AB0899 EFFECTS OF ETANERCEPT AND/OR CELECOXIB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK RESULTS OF RANDOMIZED CONTROL TRIAL

Background:

Ankylosing spondylitis (AS) is an inflammatory disease which could lead to poor health-related quality of life (QoL) due to chronic pain and impaired body function. The effects of different treament strategies including TNF-i and NSAIDs on QoL of AS patients are unknown.

Objectives:

This study aims to determine the effect of etanercept and/or celecoxib on QoL in patients with active AS.

Methods:

A post hoc analyze was conducted from a multicenter, randomized control trial. Adult patients with active AS were randomized 1:1:1 to receive etanercept 50mg qw subcutaneously or celecoxib 200mg bid oral or combined treatment for 52 weeks. Ankylosing spondylitis quality of life (ASQoL) questionnaire was used to assessed QoL in AS patients. The proportions of patients with improvements ≥ minimum clinically important differences (MCID) were assessed in ASQoL scores at week 52 using non-responder imputation. Multilevel mixed-effect models were used to compare differences of change in ASQoL scores between groups.

Results:

Of 150 patients (mean age: 32.4 years; 86% male) enrolled, 133 patients completed the study. The baseline ASQoL score was 7.38 ±4.70, with 56.67% patients having impaired QoL (ASQoL score ≥ 8). ASQoL score improved more in the combined treatment group compared to the celecoxib group [between group difference: -2.48; 95% confidence interval (CI): -3.98 to -0.98, P=0.001] and etanercept group [between group difference: -0.99; 95% CI: -2.43 to 0.45, P=0.18] over 52 weeks. Greater proportions of patients in combined treatment group reported improvements ≥ MICD in ASQoL (combined group: 72% vs. etanercept group: 60% vs. celecoxib group: 40%) although no significant difference was found between groups.

Conclusion:

Combined treatment of etanercept and celecoxib provides clinically meaningful improvements in health-related QoL in patients with active AS.

REFERENCES:

[1] Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857-72. [2] Hunter T, Sandoval D, Booth N, Holdsworth E, Deodhar A. Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey. Clinical rheumatology. 2021;40(8):3161-7. [3] Tanski W, Swiatoniowska-Lonc N, Dudek K, Jankowska-Polanska B. Benefit of Biological Drugs for Quality of Life in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Clinical Trials. Adv Exp Med Biol. 2021;1335:63-78. [4] Carbo MJG, Spoorenberg A, Maas F, Brouwer E, Bos R, Bootsma H, van der Veer E, Wink F, Arends S. Ankylosing spondylitis disease activity score is related to NSAIDs use, especially in patients treated with TNF-alpha inhibitors. PloS one. 2018;13(4):e0196281. [5] de Toledo RA, Grizzo FMF, Fernandes V, Calheiros R, Russo RT, Rosal G, Marchese LRD, Tunala R, Watanabe R, Birck MG, Julian GS, Forestiero FJ. Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAIDs for at least 12 weeks: a cross-sectional study in Brazil. Adv Rheumatol. 2022;62(1):38.

Acknowledgements:

NIL.

Disclosure of Interests:

None declared.